Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
N-terminal asparagine amidase pseudogene 3 (NTAN1P3) is a pseudogene—defined as a DNA sequence similar to a functional gene but typically incapable of encoding a functional protein product. NTAN1P3 is classified in human genomic databases as a pseudogene and, like most pseudogenes, is not considered a therapeutic target because it does not encode a functional protein, receptor, or enzyme. Pseudogenes can sometimes act as regulators of gene expression—usually through acting as decoys for microRNAs or producing regulatory noncoding RNAs—but NTAN1P3 specifically has no known function, no disease link, and no established role as a biomarker, target, or safety concern. Its biological importance, if any, remains undemonstrated[3][2][1]. Notes: - NTAN1P3 is not an active enzyme, receptor, transporter, or protein-coding gene. - As a pseudogene, it is not considered a therapeutic target. - No known drugs, biomarkers, or safety aspects are associated. - The target is *not* misspelled, but its classification as a target is incorrect, as it is not a functional or druggable molecule[3].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on N-terminal asparagine amidase pseudogene 3 (NTAN1P3).